
Weight-Loss Drugs: Promising Breakthroughs in Preventing Heart Disease and Reducing Risks
Novo Nordisk's stock is forming a fresh base after a study showed that its weight-loss drug, Wegovy, reduced the risk of heart attacks and strokes. The study, called Select, demonstrated that patients who received Wegovy were 73% less likely to develop diabetes and experienced a 28% reduction in the risk of heart attacks. This could help Novo Nordisk gain approval and insurance coverage for Wegovy in a broader population of patients. The company also tested the drug in patients with type 2 diabetes and chronic kidney disease, showing early effectiveness. Novo Nordisk's stock has a nearly perfect IBD Digital Composite Rating of 98.
